Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen A Harrison

Showing results (161-170 of 318) with videos related to

Pageof 32
Sort By:
Nature Medicine|October 16, 2023
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trialStephen A Harrison, Rebecca Taub, Guy W Neff, et al.
Plos One|June 24, 2026
Uncovering the genetic basis of crown rust resistance in a northern-by-southern oat biparental populationSuraj Sapkota, Flavia Furlan, Stephen A Harrison, et al.
Hepatology (Baltimore, Md.)|September 9, 2022
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trialRyan W Dellinger, Holly E Holmes, Tina Hu-Seliger, et al.
Hepatology (Baltimore, Md.)|July 18, 2017
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesNaga Chalasani, Zobair Younossi, Joel E Lavine, et al.
The New England Journal of Medicine|November 13, 2020
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisPhilip N Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
Journal of Graduate Medical Education|June 21, 2014
A pragmatic approach to professional and ethical dilemmasEric G Meyer, Caelan M J Ford, Robert E Thaxton, et al.
Journal of Hepatology|July 13, 2024
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled studyStephen A Harrison, Sarah K Browne, John J Suschak, et al.
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
Hepatology (Baltimore, Md.)|June 17, 2020
From NAFLD to MAFLD: Implications of a Premature Change in TerminologyZobair M Younossi, Mary E Rinella, Arun J Sanyal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2025
Rencofilstat Treatment Improves Liver Function in MASH With Advanced Fibrosis as Quantified by HepQuant DuOStephen A Harrison, Patrick Mayo, Todd Hobbs, et al.
Pageof 32

Showing results (161-170 of 318) with videos related to

Sort By:
Pageof 32
Nature Medicine|October 16, 2023
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trialStephen A Harrison, Rebecca Taub, Guy W Neff, et al.
Plos One|June 24, 2026
Uncovering the genetic basis of crown rust resistance in a northern-by-southern oat biparental populationSuraj Sapkota, Flavia Furlan, Stephen A Harrison, et al.
Hepatology (Baltimore, Md.)|September 9, 2022
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trialRyan W Dellinger, Holly E Holmes, Tina Hu-Seliger, et al.
Hepatology (Baltimore, Md.)|July 18, 2017
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesNaga Chalasani, Zobair Younossi, Joel E Lavine, et al.
The New England Journal of Medicine|November 13, 2020
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisPhilip N Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
Journal of Graduate Medical Education|June 21, 2014
A pragmatic approach to professional and ethical dilemmasEric G Meyer, Caelan M J Ford, Robert E Thaxton, et al.
Journal of Hepatology|July 13, 2024
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled studyStephen A Harrison, Sarah K Browne, John J Suschak, et al.
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
Hepatology (Baltimore, Md.)|June 17, 2020
From NAFLD to MAFLD: Implications of a Premature Change in TerminologyZobair M Younossi, Mary E Rinella, Arun J Sanyal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2025
Rencofilstat Treatment Improves Liver Function in MASH With Advanced Fibrosis as Quantified by HepQuant DuOStephen A Harrison, Patrick Mayo, Todd Hobbs, et al.
Pageof 32